Innate Pharma S.A. (IPHYF) has disclosed a new risk, in the Employment / Personnel category.
Innate Pharma S.A. faces significant business risk as it depends on a network of independent organizations, partners, advisors, and consultants to sustain its operations. With only 179 employees on record as of December 31, 2023, the necessity to scale its workforce in line with its evolving development plans is evident. However, there is no guarantee that Innate will retain access to these critical external services on demand, or that it can secure the services of equally qualified individuals or entities in the future. Should Innate struggle to effectively manage or expand its external partnerships and internal team, its ability to meet development and commercialization objectives could be compromised, potentially hindering progress and growth.
The average IPHYF stock price target is $3.36, implying 26.79% upside potential.
To learn more about Innate Pharma S.A.’s risk factors, click here.
